← All trials
NCT02870218
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2019
- Primary completion
- Jul 28, 2021
- Completion date
- Jul 28, 2021
- First posted
- Aug 17, 2016
- Last posted
- Jan 14, 2022
- Enrollment
- 150
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rose Research Center, LLCLead sponsor
- Food and Drug AdministrationCollaborator
- National Institute on Drug Abuse (NIDA)Collaborator
- National Institutes of Health (NIH)Collaborator
- Rose Research Center, LLCOverall official - principal investigator
- Rose Research Center, LLCReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.